Brexpiprazole
💊 Brand Formulations & Prices
4 brands sorted by unit price
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesBrexi is an atypical antipsychotic indicated for:
Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Treatment of schizophrenia.
Adjunctive Treatment of Major Depressive Disorder
: The recommended starting dosage for Brexpiprazole as adjunctive treatment is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. Periodically reassess to determine the continued need and appropriate dosage for treatment.
Treatment of Schizophrenia
: The recommended starting dosage for Brexpiprazole is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Brexpiprazole dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient’s clinical response and tolerability. The maximum recommended daily dosage is 4 mg.
Brexpiprazole is contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its components. Reactions have included rash, facial swelling, urticaria, and anaphylaxis.
Extrapyramidal Symptoms
Akathisia
Suicidality
QT prolongation
Weight gain
Neuroleptic malignant syndrome
Nausea
Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-
Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack)
Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring
Tardive Dyskinesia: Discontinue if clinically appropriate
Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain
Pathological Gambling and Other Compulsive Behaviors: Consider dose reduction or discontinuation
Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing Brexi if a clinically significant decline in WBC occurs in absence of other causative factors
Orthostatic Hypotension and Syncope: Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope
Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold
Brexpiprazole is an atypical antipsychotic agent. The pharmacology of Brexpiprazole is believed to be mediated by a modulatory activity at the serotonin and dopamine systems that combines partial agonist activity at serotonergic 5-HT
1A
and at dopaminergic D
2
receptors with antagonist activity at serotonergic 5-HT
2A
receptors. It shows similar high affinities at all of these receptors. Brexpiprazole also shows antagonist activity at noradrenergic a
1B/2c
receptors.